Search results
Results from the WOW.Com Content Network
Lilly's donanemab was declined accelerated approval by the FDA in January 2023, and on March 8, the agency said it would hold a meeting of its advisers to discuss the drug, further delaying its ...
The drug, donanemab, was developed by pharmaceutical company Eli Lilly and is marketed under the name Kinusla. It was approved on July 2 and is the third infusion-based drug to slow symptoms, said ...
Donanemab, sold under the brand name Kisunla, is a monoclonal antibody used for the treatment of Alzheimer's disease. [1] [2] Donanemab was developed by Eli Lilly and Company. [3] [4] The most common side effects include amyloid-related imaging abnormalities and headache. [2] Donanemab was approved for medical use in the United States in July 2024.
The Alzheimer’s drug Leqembi, the first medicine proven to slow the course of the disease, may be able to be given as a set of two weekly shots at home, a study from drugmaker Eisai suggests ...
The principal for obstetric management of COVID-19 include rapid detection, isolation, and testing, profound preventive measures, regular monitoring of fetus as well as of uterine contractions, peculiar case-to-case delivery planning based on severity of symptoms, and appropriate post-natal measures for preventing infection.
The COVID-19 pandemic was confirmed to have reached the U.S. state of Pennsylvania in March 2020. As of October 7, 2021 [update] , the Pennsylvania Department of Health has confirmed 1,464,264 cumulative cases and 29,814 deaths in the state. [ 1 ]
Lecanemab may cause amyloid-related imaging abnormalities (ARIA). ARIA is often asymptomatic, but serious and life-threatening events rarely may occur.ARIA most commonly presents as temporary swelling of the brain that usually resolves over time and may be accompanied by small spots of bleeding in or on the surface of the brain, though some people may have symptoms such as headache, confusion ...
For premium support please call: 800-290-4726 more ways to reach us